tert-Butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamido)piperidine-1-carboxylate

Catalog No. :
ACJARF239
CAS No. :
1610612-52-6
Molecular Formula :
C23H35BN2O5
Molecular Weight :
430.35

IUPAC Name:tert-butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamido)piperidine-1-carboxylate

tert-Butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamido)piperidine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g98%$1318.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamido)piperidine-1-carboxylate
IUPAC Nametert-butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamido)piperidine-1-carboxylate
MDL No.MFCD31716298
Molecular FormulaC23H35BN2O5
Molecular Weight430.35
SMILESO=C(N1CCC(NC(C2=CC=C(B3OC(C)(C)C(C)(C)O3)C=C2)=O)CC1)OC(C)(C)C
InChI KeyKBJGDFAQLGYTFU-UHFFFAOYSA-N
Synonym4-[4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoylamino]-piperidine-1-carboxylic acid tert-butyl ester;1-Piperidinecarboxylic acid, 4-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl]amino]-, 1,1-dimethylethyl ester
CAS No.1610612-52-6

Synthetic Route by SureRoute

1. ACJARF239 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACLEYR154 route compound structure diagram
    --
  2. Plus
  3. ACFXIR245 route compound structure diagram
    ACFXIR245180516-87-4 In Stock
  4. Then
  5. ACJARF239 route product structure diagram
    ACJARF2391610612-52-6
Inquiry

2. ACJARF239 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  4. Then
  5. ACJARF239 route product structure diagram
    ACJARF2391610612-52-6
Inquiry

Comments (0)